ALVO Latest Press Releases

-- November 2, 2026 --

Alvotech to Present at Upcoming Investor Conferences in November Globe Newswire 7:00 AM

-- October 28, 2026 --

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 Globe Newswire 7:00 AM

-- October 20, 2026 --

Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process That More Than Doubles Output Per Batch Globe Newswire 4:30 AM

-- October 14, 2026 --

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea 8 mg Globe Newswire 4:30 AM

-- October 6, 2026 --

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply Globe Newswire 4:36 PM

-- October 5, 2026 --

FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira Globe Newswire 4:00 AM

-- August 31, 2026 --

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations Globe Newswire 4:30 AM

-- August 27, 2026 --

Alvotech to present at upcoming investor conferences in September Globe Newswire 8:00 AM

-- August 21, 2026 --

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets Globe Newswire 9:00 AM

-- August 19, 2026 --

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update Globe Newswire 4:30 PM

-- August 10, 2026 --

Alvotech to Report Financial Results for H1 2026 Globe Newswire 8:00 AM

-- July 29, 2026 --

Alvotech announces successful closure of FDA inspection of manufacturing facility Globe Newswire 9:25 AM

-- July 1, 2026 --

Alvotech further strengthens liquidity by securing term loan facility of $75 million Globe Newswire 4:00 AM

-- June 18, 2026 --

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement Globe Newswire 5:51 AM

-- June 15, 2026 --

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement Globe Newswire 11:59 PM

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares Globe Newswire 4:01 PM

-- June 8, 2026 --

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio Globe Newswire 4:00 AM

Market Data Delayed 15 Minutes